Jump to navigation Jump to search
Tetrazepam Structural Formulae.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
ATC code
Legal status
Legal status
  • Schedule IV US
Pharmacokinetic data
Elimination half-life3–26 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass288.772
3D model (JSmol)

WikiDoc Resources for Tetrazepam


Most recent articles on Tetrazepam

Most cited articles on Tetrazepam

Review articles on Tetrazepam

Articles on Tetrazepam in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tetrazepam

Images of Tetrazepam

Photos of Tetrazepam

Podcasts & MP3s on Tetrazepam

Videos on Tetrazepam

Evidence Based Medicine

Cochrane Collaboration on Tetrazepam

Bandolier on Tetrazepam

TRIP on Tetrazepam

Clinical Trials

Ongoing Trials on Tetrazepam at Clinical Trials.gov

Trial results on Tetrazepam

Clinical Trials on Tetrazepam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tetrazepam

NICE Guidance on Tetrazepam


FDA on Tetrazepam

CDC on Tetrazepam


Books on Tetrazepam


Tetrazepam in the news

Be alerted to news on Tetrazepam

News trends on Tetrazepam


Blogs on Tetrazepam


Definitions of Tetrazepam

Patient Resources / Community

Patient resources on Tetrazepam

Discussion groups on Tetrazepam

Patient Handouts on Tetrazepam

Directions to Hospitals Treating Tetrazepam

Risk calculators and risk factors for Tetrazepam

Healthcare Provider Resources

Symptoms of Tetrazepam

Causes & Risk Factors for Tetrazepam

Diagnostic studies for Tetrazepam

Treatment of Tetrazepam

Continuing Medical Education (CME)

CME Programs on Tetrazepam


Tetrazepam en Espanol

Tetrazepam en Francais


Tetrazepam in the Marketplace

Patents on Tetrazepam

Experimental / Informatics

List of terms related to Tetrazepam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Tetrazepam[1] (is marketed under the following brand names, Clinoxan, Epsipam, Myolastan, Musaril, Relaxam and Spasmorelax) is a benzodiazepine derivative with anticonvulsant, anxiolytic, hypnotic and muscle relaxant properties. It was formerly used mainly in Austria, France, Belgium, Germany and Spain to treat muscle spasm, anxiety disorders such as panic attacks, or more rarely to treat depression, premenstrual syndrome or agoraphobia. Tetrazepam has relatively little sedative effect at low doses while still producing useful muscle relaxation and anxiety relief. The Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMD(h)) endorsed the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation to suspend the marketing authorisations of tetrazepam-containing medicines across the European Union (EU) in April 2013.[2] The European Commission has confirmed the suspension of the marketing authorisations for Tetrazepam in Europe because of cutaneous toxicity, effective from the 1 August 2013.[3]

Delayed type 4 allergic hypersensitivity reactions including aculopapular exanthema, erythematous rash, urticarial eruption, erythema multiforme, photodermatitis, eczema and Stevens–Johnson syndrome can occasionally occur as a result of tetrazepam exposure. These hypersensitivity reactions to tetrazepam share no cross-reactivity with other benzodiazepines.[4]


Tetrazepam is used therapeutically as a muscle relaxant.[5][6]


The indicated adult dose for muscle spasm is 25 mg to 150 mg per day, increased if necessary to a maximum of 300 mg per day, in divided doses. Tetrazepam is not generally recommended for use in children, except on the advice of a specialist.

Tetrazepam is only available in one strength and formulation, 50 mg tablets. The benzodiazepine equivalent of tetrazepam is approximately 100mg of tetrazepam = 10 mg of diazepam.[7]

Adverse effects

Allergic reactions to tetrazepam occasionally occur involving the skin.[4]

Allergic reactions can develop to tetrazepam[8][9] and it is considered to be a potential allergen.[10][11] Drug rash and drug-induced eosinophilia with systemic symptoms is a known complication of tetrazepam exposure.[12][13] These hypersensitive allergic reactions can be of the delayed type.[14][15][16]

Toxic epidermal necrolysis has occurred from the use of tetrazepam[17][18] including at least one reported death.[19] Stevens–Johnson syndrome and erythema multiforme has been reported from use of tetrazepam. Cross-reactivity with other benzodiazepines does not typically occur in such patients.[20][21][22] Exanthema[23] and eczema may occur.[24] The lack of cross-reactivity with other benzodiazepines is believed to be due to the molecular structure of tetrazepam.[25][26] Photodermatitis[27] and phototoxicity have also been reported.[28] Occupational contact allergy can also develop from regularly handling tetrazepam.[29][30] Airborne contact dermatitis can also occur as an allergy which can develop from occupational exposure.[31]

Patch testing has been used successfully to demonstrate tetrazepam allergy.[32][33] Oral testing can also be used. Skin prick tests are not always accurate and may produce false negatives.[34]

Drowsiness is a common side effect of tetrazepam.[35] A reduction in muscle force can occur.[36] Myasthenia gravis, a condition characterised by severe muscle weakness is another potential adverse effect from tetrazepam.[37] Cardiovascular and respiratory adverse effects can occur with tetrazepam similar to other benzodiazepines.[26]

Tolerance, dependence and withdrawal

Prolonged use, as with all benzodiazepines, should be avoided, as tolerance occurs and there is a risk of benzodiazepine dependence and a benzodiazepine withdrawal syndrome after stopping or reducing dosage.[26]


Tetrazepam, like other benzodiazepines is a drug which is very frequently present in cases of overdose. These overdoses are often mixed overdoses, i.e. a mixture of other benzodiazepines or other drug classes with tetrazepam.[38][39]

Contraindications and special caution

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.[40]


Tetrazepam is an unusual benzodiazepine in its molecular structure as it has cyclohexenyl group which has substituted the typical 5-phenyl moiety seen in other benzodiazepines.[41] Tetrazepam, is rapidly absorbed after oral administration, within 45 mins and reaches peak plasma levels in less than 2 hours. It is classed as an intermediate acting benzodiazepine with an elimination half-life of approximately 15 hours. It is primarily metabolised to the inactive metabolites 3-hydroxy-tetrazepam and norhydroxytetrazepam.[41][42] The pharmacological effects of tetrazepam are significantly less potent when compared against diazepam, in animal studies.[43] Tetrazepam is a benzodiazepine site agonist and binds unselectively to type 1 and type 2 benzodiazepine site types as well as to peripheral benzodiazepine receptors.[44] The muscle relaxant properties of tetrazepam are most likely due to a reduction of calcium influx.[45] Small amounts of diazepam as well as the active metabolites of diazepam are produced from metabolism of tetrazepam.[46][47] The metabolism of tetrazepam has led to false accusations of prisoners prescribed tetrazepam of taking illicit diazepam; this can lead to increased prison sentences for prisoners.[41]


Tetrazepam as with other benzodiazepines is sometimes abused. It is sometimes abused to incapacitate a victim in order to carry out a drug-facilitated crime.[48] or abused in order to achieve a state of intoxication.[49] Tetrazepam's abuse for to carry out drug facilitated crimes may be less however, than other benzodiazepines due to its reduced hypnotic properties.[50]

See also


  1. NL Patent 6600095
  2. Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh, European Medicines Agency, published 29 April 2013
  3. Ruhen der Zuhlassung aller Tetrazepam-haltiger Arzneimittel, Sanofi-Avensis Deutschland GmbH (German), published June 2013
  4. 4.0 4.1 Thomas, E; Bellón, T; Barranco, P; Padial, A; Tapia, B; Morel, E; Alves-Ferreira, J; Martín-Esteban, M (2008). "Acute generalized exanthematous pustulosis due to tetrazepam" (PDF). Journal of Investigational Allergology and Clinical Immunology. 18 (2): 119–22. ISSN 1018-9068. PMID 18447141.
  5. Simiand, J; Keane, PE; Biziere, K; Soubrie, P (January 1989). "Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants". Archives internationales de pharmacodynamie et de therapie. 297: 272–85. ISSN 0301-4533. PMID 2567153.
  6. Perez-Guerrero, C; Herrera, MD; Marhuenda, E (November 1996). "Relaxant effect of tetrazepam on rat uterine smooth muscle: role of calcium movement". The Journal of pharmacy and pharmacology. 48 (11): 1169–73. doi:10.1111/j.2042-7158.1996.tb03915.x. ISSN 0022-3573. PMID 8961167.
  7. "Benzodiazepine Names". non-benzodiazepines.org.uk. Retrieved 2009-04-05.
  8. Camarasa, JG; Serra-Baldrich, E (April 1990). "Tetrazepam allergy detected by patch test". Contact dermatitis. 22 (4): 246. doi:10.1111/j.1600-0536.1990.tb01587.x. ISSN 0105-1873. PMID 2140761.
  9. Collet, E; Dalac, S; Morvan, C; Sgro, C; Lambert, D (April 1992). "Tetrazepam allergy once more detected by patch test". Contact dermatitis. 26 (4): 281. doi:10.1111/j.1600-0536.1992.tb00259.x. ISSN 0105-1873. PMID 1356710.
  10. Ortiz-Frutos, FJ; Alonso, J; Hergueta, JP; Quintana, I; Iglesias, L (July 1995). "Tetrazepam: an allergen with several clinical expressions". Contact dermatitis. 33 (1): 63–5. doi:10.1111/j.1600-0536.1995.tb00462.x. ISSN 0105-1873. PMID 7493477.
  11. Del Pozo, MD; Blasco, A; Lobera, T (November 1999). "Tetrazepam allergy". Allergy. 54 (11): 1226–7. doi:10.1034/j.1398-9995.1999.00362.x. ISSN 0105-4538. PMID 10604563.
  12. Dinić-Uzurov, V; Lalosević, V; Milosević, I; Urosević, I; Lalosević, D; Popović, S (November 2007). "Current differential diagnosis of hypereosinophilic syndrome". Medicinski pregled. 60 (11–12): 581–6. doi:10.2298/MPNS0712581D. ISSN 0025-8105. PMID 18666600.
  13. Bachmeyer, C; Assier, H; Roujeau, JC; Blum, L (July 2008). "Probable drug rash with eosinophilia and systemic symptoms syndrome related to tetrazepam". Journal of the European Academy of Dermatology and Venereology : JEADV. 22 (7): 887–9. doi:10.1111/j.1468-3083.2007.02490.x. ISSN 0926-9959. PMID 18031497.
  14. Blanco, R; Díez-Gómez, ML; Gala, G; Quirce, S (November 1997). "Delayed hypersensitivity to tetrazepam". Allergy. 52 (11): 1146–7. doi:10.1111/j.1398-9995.1997.tb00194.x. ISSN 0105-4538. PMID 9404574.
  15. Ortega, NR; Barranco, P; López Serrano, C; Romualdo, L; Mora, C (February 1996). "Delayed cell-mediated hypersensitivity to tetrazepam". Contact dermatitis. 34 (2): 139. doi:10.1111/j.1600-0536.1996.tb02147.x. ISSN 0105-1873. PMID 8681544.
  16. Kämpgen, E; Bürger, T; Bröcker, EB; Klein, CE (November 1995). "Cross-reactive type IV hypersensitivity reactions to benzodiazepines revealed by patch testing". Contact dermatitis. 33 (5): 356–7. doi:10.1111/j.1600-0536.1995.tb02060.x. ISSN 0105-1873. PMID 8565501.
  17. Delesalle, F; Carpentier, O; Guatier, S; Delaporte, E (April 2006). "Toxic epidermal necrolysis caused by tetrazepam". International Journal of Dermatology. 45 (4): 480. doi:10.1111/j.1365-4632.2006.02654.x. ISSN 0011-9059. PMID 16650186.
  18. Wolf, R; Orion, E; Davidovici, B (October 2006). "Toxic epidermal necrolysis caused by tetrazepam". International Journal of Dermatology. 45 (10): 1260–1. doi:10.1111/j.1365-4632.2006.03061.x. ISSN 0011-9059. PMID 17040464.
  19. Lagnaoui, R; Ramanampamonjy, R; Julliac, B; Haramburu, F; Ticolat, R (March 2001). "Fatal toxic epidermal necrolysis associated with tetrazepam". Therapie. 56 (2): 187–8. ISSN 0040-5957. PMID 11471372.
  20. Pirker, C; Misic, A; Brinkmeier, T; Frosch, PJ (September 2002). "Tetrazepam drug sensitivity – usefulness of the patch test". Contact dermatitis. 47 (3): 135–8. doi:10.1034/j.1600-0536.2002.470302.x. ISSN 0105-1873. PMID 12492544.
  21. Sánchez, I; García-Abujeta, JL; Fernández, L; Rodríguez, F; Quiñones, D; Duque, S; López, R; Jerez, J (2 March 1998). "Stevens–Johnson syndrome from tetrazepam". Allergologia et immunopathologia. 26 (2): 55–7. ISSN 0301-0546. PMID 9645262.
  22. Rodríguez Vázquez, M; Ortiz De Frutos, J; Del Río Reyes, R; Iglesias Díez, L (September 2000). "Erythema multiforme by tetrazepam". Medicina clinica. 115 (9): 359. doi:10.1016/s0025-7753(00)71559-4. ISSN 0025-7753. PMID 11093904.
  23. Ghislain, PD; Roussel, S; Bouffioux, B; Delescluse, J (December 2000). "Tetrazepam (Myolastan)-induced exanthema: positive patch tests in 2 cases". Annales de dermatologie et de vénéréologie. 127 (12): 1094–6. ISSN 0151-9638. PMID 11173688.
  24. Breuer, K; Worm, M; Skudlik, C; Schröder, C; John, SM (April 2009). "Occupational airborne contact allergy to tetrazepam in a geriatric nurse". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 7 (10): 896–8. doi:10.1111/j.1610-0387.2009.07096.x. ISSN 1610-0379. PMID 19453384.
  25. Barbaud, A; Girault, PY; Schmutz, JL; Weber-Muller, F; Trechot, P (July 2009). "No cross-reactions between tetrazepam and other benzodiazepines: a possible chemical explanation". Contact dermatitis. 61 (1): 53–6. doi:10.1111/j.1600-0536.2009.01558.x. ISSN 0105-1873. PMID 19659970.
  26. 26.0 26.1 26.2 Cabrerizo Ballesteros, S; Méndez Alcalde, JD; Sánchez Alonso, A (2007). "Erythema multiforme to tetrazepam" (PDF). Journal of Investigational Allergology and Clinical Immunology. 17 (3): 205–6. ISSN 1018-9068. PMID 17583114.
  27. Quiñones, D; Sanchez, I; Alonso, S; Garcia-Abujeta, JL; Fernandez, L; Rodriguez, F; Martin-Gil, D; Jerez, J (August 1998). "Photodermatitis from tetrazepam". Contact dermatitis. 39 (2): 84. doi:10.1111/j.1600-0536.1998.tb05840.x. ISSN 0105-1873. PMID 9746190.
  28. Schwedler, S; Mempel, M; Schmidt, T; Abeck, D; Ring, J (1998). "Phototoxicity to tetrazepam – A new adverse reaction". Dermatology (Basel, Switzerland). 197 (2): 193–4. ISSN 1018-8665. PMID 9840980.
  29. Choquet-Kastylevsky, G; Testud, F; Chalmet, P; Lecuyer-Kudela, S; Descotes, J (June 2001). "Occupational contact allergy to tetrazepam". Contact dermatitis. 44 (6): 372. doi:10.1034/j.1600-0536.2001.440609-7.x. ISSN 0105-1873. PMID 11417526.
  30. Lepp, U; Zabel, P; Greinert, U (November 2003). "Occupational airborne contact allergy to tetrazepam". Contact dermatitis. 49 (5): 260–1. doi:10.1111/j.0105-1873.2003.0225c.x. ISSN 0105-1873. PMID 14996051.
  31. Ferran, M; Giménez-Arnau, A; Luque, S; Berenguer, N; Iglesias, M; Pujol, RM (March 2005). "Occupational airborne contact dermatitis from sporadic exposure to tetrazepam during machine maintenance". Contact dermatitis. 52 (3): 173–4. doi:10.1111/j.0105-1873.2005.0548o.x. ISSN 0105-1873. PMID 15811045.
  32. Barbaud, A; Gonçalo, M; Bruynzeel, D; Bircher, A; European Society Of Contact (December 2001). "Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions". Contact dermatitis. 45 (6): 321–8. doi:10.1034/j.1600-0536.2001.450601.x. ISSN 0105-1873. PMID 11846746.
  33. Barbaud, A; Trechot, P; Reichert-Penetrat, S; Granel, F; Schmutz, JL (April 2001). "The usefulness of patch testing on the previously most severely affected site in a cutaneous adverse drug reaction to tetrazepam". Contact dermatitis. 44 (4): 259–60. doi:10.1034/j.1600-0536.2001.440409-15.x. ISSN 0105-1873. PMID 11336014.
  34. Sánchez-Morillas, L; Laguna-Martínez, JJ; Reaño-Martos, M; Rojo-Andrés, E; Ubeda, PG (2008). "Systemic dermatitis due to tetrazepam" (PDF). Journal of Investigational Allergology and Clinical Immunology. 18 (5): 404–6. ISSN 1018-9068. PMID 18973107.
  35. Rode, G; Maupas, E; Luaute, J; Courtois-Jacquin, S; Boisson, D (May 2003). "Medical treatment of spasticity". Neuro-Chirurgie. 49 (2–3 Pt 2): 247–55. ISSN 0028-3770. PMID 12746699.
  36. Lobisch, M; Schaffler, K; Wauschkuhn, H; Nickel, B (March 1996). "Clinical pilot study of the myogenic effects of flupirtine in comparison to tetrazepam and placebo". Arzneimittel-Forschung. 46 (3): 293–8. ISSN 0004-4172. PMID 8901152.
  37. Vargas Ortega, I; Canora Lebrato, J; Díez Ruiz, A; Rico Irles, J (December 2000). "Myasthenia gravis after tetrazepam treatment". Anales de medicina interna (Madrid, Spain : 1984). 17 (12): 669. ISSN 0212-7199. PMID 11213590.
  38. Zevzikovas, A; Bertulyte, A; Dirse, V; Ivanauskas, L (2003). "Determination of benzodiazepine derivatives mixture by high performance liquid chromatography". Medicina (Kaunas, Lithuania). 39 Suppl 2: 30–6. ISSN 1010-660X. PMID 14617855.
  39. Zevzikovas, A; Kiliuviene, G; Ivanauskas, L; Dirse, V (2002). "Analysis of benzodiazepine derivative mixture by gas–liquid chromatography" (PDF). Medicina (Kaunas, Lithuania) (in lithuanian). 38 (3): 316–20. ISSN 1010-660X. PMID 12474705.
  40. Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr. 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
  41. 41.0 41.1 41.2 Pavlic, M; Libiseller, K; Grubwieser, P; Schubert, H; Rabl, W (May 2007). "Medicolegal aspects of tetrazepam metabolism" (PDF). International journal of legal medicine. 121 (3): 169–74. doi:10.1007/s00414-006-0118-6. ISSN 0937-9827. PMID 17021899.
  42. Baumgärtner, MG; Cautreels, W; Langenbahn, H (1984). "Biotransformation and pharmacokinetics of tetrazepam in man". Arzneimittel-Forschung. 34 (6): 724–9. ISSN 0004-4172. PMID 6148954.
  43. Keane, PE; Simiand, J; Morre, M; Biziere, K (May 1988). "Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents". The Journal of Pharmacology and Experimental Therapeutics. 245 (2): 692–8. ISSN 0022-3565. PMID 2896794.
  44. Keane, PE; Bachy, A; Morre, M; Biziere, K (May 1988). "Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites". The Journal of Pharmacology and Experimental Therapeutics. 245 (2): 699–705. ISSN 0022-3565. PMID 2896795.
  45. Pérez-Guerrero, C; Suárez, J; Herrera, MD; Marhuenda, E (May 1997). "Spasmolytic effects of tetrazepam on rat duodenum and guinea-pig ileum". Pharmacological research : the official journal of the Italian Pharmacological Society. 35 (5): 493–7. doi:10.1006/phrs.1997.0173. ISSN 1043-6618. PMID 9299217.
  46. Baumann, A; Lohmann, W; Schubert, B; Oberacher, H; Karst, U (April 2009). "Metabolic studies of tetrazepam based on electrochemical simulation in comparison to in vivo and in vitro methods". Journal of Chromatography A. 1216 (15): 3192–8. doi:10.1016/j.chroma.2009.02.001. ISSN 0021-9673. PMID 19233363.
  47. Schubert, B; Pavlic, M; Libiseller, K; Oberacher, H (December 2008). "Unraveling the metabolic transformation of tetrazepam to diazepam with mass spectrometric methods". Analytical and Bioanalytical Chemistry. 392 (7–8): 1299–308. doi:10.1007/s00216-008-2447-4. ISSN 1618-2642. PMID 18949465.
  48. Concheiro, M; Villain, M; Bouchet, S; Ludes, B; López-Rivadulla, M; Kintz, P (October 2005). "Windows of detection of tetrazepam in urine, oral fluid, beard, and hair, with a special focus on drug-facilitated crimes". Therapeutic drug monitoring. 27 (5): 565–70. doi:10.1097/01.ftd.0000164610.14808.45. ISSN 0163-4356. PMID 16175127.
  49. Kintz, P; Villain, M; Concheiro, M; Cirimele, V (June 2005). "Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS". Forensic Science International. 150 (2–3): 213–20. doi:10.1016/j.forsciint.2004.12.040. ISSN 0379-0738. PMID 15944062.
  50. Laloup, M; Fernandez Mdel, M; Wood, M; Maes, V; De Boeck, G; Vanbeckevoort, Y; Samyn, N (August 2007). "Detection of diazepam in urine, hair and preserved oral fluid samples with LC-MS-MS after single and repeated administration of Myolastan and Valium" (PDF). Analytical and Bioanalytical Chemistry. 388 (7): 1545–56. doi:10.1007/s00216-007-1297-9. ISSN 1618-2642. PMID 17468852.